Business
Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
WALTHAM, Mass., Dec. 9, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., Dec. 9, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the publication of a preclinical report demonstrating that selective inhibition of the Menin-MLL interaction, provides consistent anti-proliferative and anti-leukemic activity across multiple mixed lineage leukemia rearranged (MLLr) samples. The article, \"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia,\" was published in the December 9 issue of Cancer Cell; the article is also available online.\nThis study, which was led by researchers at Dana-Farber Cancer Institute and Children's Cancer Institute, Sydney, Australia, examined the activity of VTP-50469, a close analog of the clinical lead SNDX-5613, against a range of MLLr harboring cell lines and patient-derived xenograft (PDX) models. Cell lines carrying MLL rearrangements were selectively responsive to VTP-50469, triggering disruption of menin containing transcription complexes and causing changes to gene expression that induced terminal differentiation and cell death. In PDX models, of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) subtypes of MLLr, single agent treatment with the Menin-MLL interaction inhibitor significantly reduced leukemia burden and led to profound survival benefit, with many mice remaining disease free more than one year after treatment. \n\"The newly developed Menin-MLL inhibitor demonstrated remarkable single-agent activity in PDX models of human MLL-rearranged leukemia including disease eradication,\" said Scott A. Armstrong, M.D., Ph.D., President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and Chairman, Department of Pediatric Oncology, Dana-Farber Cancer Institute and senior author of the study. \"This level of activity is unusual for single agent treatments in leukemia models.\" \n\"For patients with genetically-defined acute leukemias, there exists a dire unmet need for novel and effective therapeutic options,\" said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. \"We are encouraged by these preclinical data, which continue to support our belief that SNDX-5613, our lead Menin...